Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of CP-751,871 in refractory metastatic colorectal adenocarcinoma
2007-004787-49Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of figitumumab in colorectal adenocarcinoma, metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC), sponsored by Pfizer. Primary endpoint: Overall survival at 6 months. Started Oct 2007; status: completed.
02
Drugs
figitumumab
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-004787-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004787-49.